Symposium: AHA Council on Basic Cardiovascular Sciences

描述(由申请人提供)： 这项为期多年的会议赠款申请(R13)寻求NHLBI的支持，以建立由世界领先的心血管科学家组织--美国心脏协会基础心血管科学理事会主办的年度研讨会。作为在阿西洛马尔、雪鸟和西雅图举行的更零星会议的演变，这次年度会议将进一步推动从分子、细胞和组织到器官、器官系统和生物体无缝连续地了解正常和异常心血管生物学的科学使命。在目前所谓的“后基因组”时代，随着人类基因组测序的完成，我们的许多观众都强烈关注的一个焦点是将基因与心血管系统的功能联系起来。通过意向，我们已经取代了前几年使用的交替使用的“心力衰竭”和“脑梗塞”主题，将更全面和更广泛的科学重点放在功能基因组学上。2004年，这次会议的统一科学主题将是全基因组对心血管系统压力的反应，这是一个特别具有当前吸引力的话题。心脏病方面的国家战略目标不能仅靠现成的药物、设备和生活方式的改变来实现。主要的治疗挑战包括通过抑制心肌细胞死亡、通过促进细胞存活信号以及通过供应或激活干细胞作为实现心肌修复的手段来挽救急性缺血性心脏病和充血性心力衰竭的心肌。成体干细胞用于这些目的的潜在效用甚至超过了几年前最乐观的预测，这一点从全球已在进行的临床试验的数量中得到了反映。第一届年度研讨会将于2004年7月14日至18日在华盛顿州史蒂文森举行，由迈克尔·施奈德博士、艾弗·本杰明博士、伊塞伊·小室博士和斯蒂芬妮·迪梅勒博士组织。施奈德博士担任这项具有里程碑意义的会议拨款提案的私人投资。

DESCRIPTION (provided by applicant): This multiple-year conference grant application (R13) seeks NHLBI support towards the establishment of an annual symposium sponsored by the American Heart Association's Council on Basic Cardiovascular Sciences, the world's leading organization of cardiovascular scientists. An evolution of more sporadic meetings held in Asilomar, Snowbird, and Seattle, this annual conference would further the scientific mission to understand normal and abnormal cardiovascular biology in seamless continuity from molecules, cells, and tissues to organs, organ systems, and organisms. In the current so-called "post-genomic" era, with the human genome sequencing complete, an intensely shared focus for much of our audience is linking genes to function in the cardiovascular system. By intent, we have superceded the alternating themes of "heart failure" and "infarction" used in prior years, with a much more integrated and broadly based scientific focus on functional genomics. For 2004, the unifying scientific theme of this conference will be the genome-wide response to stress in the cardiovascular system, a topic of especially current appeal. National strategic goals in heart disease cannot be met with off-the-shelf drugs, devices, and life-style modifications alone. Major therapeutic challenges include salvaging myocardium in acute ischemic heart disease and in congestive heart failure by inhibiting cardiac muscle cell death, by promoting cell survival signals, and by supplying or activating stem cells as a means to achieve myocardial repair. The potential utility of adult stem cells for these purpose exceeds even the most optimistic projections of a few years ago, and is reflected by the number of clinical trials already underway worldwide. The 1st Annual Symposium will be held July 14-18, 2004, in Stevenson, Washington, and was organized by Drs. Michael Schneider, Ivor Benjamin, Issei Komuro, and Stefanie Dimmeler. Dr. Schneider serves as the PI for this landmark conference grant proposal.